Clinical efficacy and safety of docetaxel plus cisplatin combined with concurrent radiation in the treatment of stage Ⅲnon-small cell lung cancer
10.13699/j.cnki.1001-6821.2015.21.005
- VernacularTitle:多西他赛顺铂联合同步放疗治疗Ⅲ期非小细胞肺癌的临床疗效及安全性
- Author:
Chun-Lin KE
1
;
Rong-Gang LUO
;
Jian-Bo LIN
;
Bo LIU
;
Xu LI
;
Fan-Cai LAI
Author Information
1. 福建医科大学 附属第一医院 胸外科
- Keywords:
neoadjuvant;
non-small cell lung cancer;
docetaxel;
cisplatin;
chemoradiation
- From:
The Chinese Journal of Clinical Pharmacology
2015;(21):2102-2104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects of docetaxel plus cisplatin combined with concurrent radiation in the treatment of stageⅢ non-small cell lung cancer ( NSCLC ) .Methods Twenty patients with stageⅢNSCLC were recruited.Patients were treated with docetaxel 20 mg? m-2 intravenous drop infusion plus cisplatin 30 mg? m-2 intravenous drop infusion on day 1.At the same time, the patients also received radiation with 2 Gy qd for 5 times per week with the total dosage of 30 Gy.Two weeks after the chemoradiation, patients received the clinical stage evaluation and surgery. The clinical efficacy, surgical resection rate and survival time were evaluated.Results Eighteen cases finished the 3 cycle chemoradiation. For the 18 subjects, 2 cases achieved complete response, 6 achieved partial response, 2 achieved sta-ble disease and 2 achieved progress disease with the objective response rate of 44.4%.Of the 18 cases, 11 patients received operation, with the completed removal rate of 81.8%, two patients with pleural metastasis or tumor invasion of the large vessel were not given complete removal.The median survivals were 22.5 months and 10.1 months in the operation group and non-operation group with statistical difference( P<0.05).Two cases drop out of the trial for severe adverse event.Conclusion Docetaxel plus cisplatin combined with concurrent radiation can improve the operation rate for stage Ⅲnon-small cell lung cancer.
